HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $275
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $225 to $275.
November 13, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals' stock may see a positive short term impact due to the raised price target from $225 to $275 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target for Madrigal Pharmaceuticals by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in the company's potential, which could lead to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100